Literature DB >> 11895036

The WHO classification of tumors of the nervous system.

Paul Kleihues1, David N Louis, Bernd W Scheithauer, Lucy B Rorke, Guido Reifenberger, Peter C Burger, Webster K Cavenee.   

Abstract

The new World Health Organization (WHO) classification of nervous system tumors, published in 2000, emerged from a 1999 international consensus conference of neuropathologists. New entities include chordoid glioma of the third ventricle, cerebellar liponeurocytoma, atypical teratoid/rhabdoid tumor, and perineurioma. Several histological variants were added, including tanycytic ependymoma, large cell medulloblastoma, and rhabdoid meningioma. The WHO grading scheme was updated and, for meningiomas, extensively revised. In recognition of the emerging role of molecular diagnostic approaches to tumor classification, genetic profiles have been emphasized, as in the distinct subtypes of glioblastoma and the already clinically useful 1p and 19q markers for oligodendroglioma and 22q/INI1 for atypical teratoid/rhabdoid tumors. In accord with the new WHO Blue Book series, the actual classification is accompanied by extensive descriptions and illustrations of clinicopathological characteristics of each tumor type, including molecular genetic features, predictive factors, and separate chapters on inherited tumor syndromes. The 2000 WHO classification of nervous system tumors aims at being used and implemented by the neuro-oncology and biomedical research communities worldwide.

Entities:  

Mesh:

Year:  2002        PMID: 11895036     DOI: 10.1093/jnen/61.3.215

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  511 in total

1.  Magnetic resonance imaging and computed tomography findings in pediatric giant cell glioblastoma.

Authors:  L Zipp; K M Schwartz; E Hewer; Y Yu; C Stippich; J M Slopis
Journal:  Clin Neuroradiol       Date:  2012-12       Impact factor: 3.649

2.  CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.

Authors:  Tao Sun; Scott M Gianino; Erin Jackson; David Piwnica-Worms; David H Gutmann; Joshua B Rubin
Journal:  J Neuroimmunol       Date:  2010-07-27       Impact factor: 3.478

3.  De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.

Authors:  Matthieu Peyre; Guillaume Gauchotte; Marine Giry; Sébastien Froehlich; Johan Pallud; Thomas Graillon; Franck Bielle; Dominique Cazals-Hatem; Pascale Varlet; Dominique Figarella-Branger; Hugues Loiseau; Michel Kalamarides
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

4.  Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma.

Authors:  Kaisorn L Chaichana; Ignacio Jusue-Torres; Rodrigo Navarro-Ramirez; Shaan M Raza; Maria Pascual-Gallego; Aly Ibrahim; Marta Hernandez-Hermann; Luis Gomez; Xiaobu Ye; Jon D Weingart; Alessandro Olivi; Jaishri Blakeley; Gary L Gallia; Michael Lim; Henry Brem; Alfredo Quinones-Hinojosa
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

5.  Adding 11C-methionine PET to the EORTC prognostic factors in grade 2 gliomas.

Authors:  A Smits; E Westerberg; D Ribom
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-21       Impact factor: 9.236

6.  The influence of age on the histological grading of meningiomas.

Authors:  Jae-Sung Park; Burak Sade; Soichi Oya; Chong Gue Kim; Joung H Lee
Journal:  Neurosurg Rev       Date:  2014-04-29       Impact factor: 3.042

7.  Pitfalls in the assessment of disability in individuals with low-grade gliomas.

Authors:  Anneli Påhlson; Lena Ek; Gerd Ahlström; Anja Smits
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

8.  Molecular heterogeneity of meningioma with INI1 mutation.

Authors:  P Rieske; M Zakrzewska; S Piaskowski; D Jaskólski; B Sikorska; W Papierz; K Zakrzewski; P P Liberski
Journal:  Mol Pathol       Date:  2003-10

9.  Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma.

Authors:  Meghan C Brown; Izabela Staniszewska; Philip Lazarovici; George P Tuszynski; Luis Del Valle; Cezary Marcinkiewicz
Journal:  Neuro Oncol       Date:  2008-12       Impact factor: 12.300

Review 10.  Chemotherapy for malignant brain tumors of childhood.

Authors:  Nicholas G Gottardo; Amar Gajjar
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.